Literature DB >> 26655220

Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells.

Murielle M Akpa1, Diana Iglesias2, LeeLee Chu2, Antonin Thiébaut2, Ida Jentoft2, Leah Hammond2, Elena Torban3, Paul R Goodyer4.   

Abstract

Hereditary forms of Wilms arise from developmentally arrested clones of renal progenitor cells with biallelic mutations of WT1; recently, it has been found that Wilms tumors may also be associated with biallelic mutations in DICER1 or DROSHA, crucial for miRNA biogenesis. We have previously shown that a critical role for WT1 during normal nephrogenesis is to suppress transcription of the Polycomb group protein, EZH2, thereby de-repressing genes in the differentiation cascade. Here we show that WT1 also suppresses translation of EZH2. All major WT1 isoforms induce an array of miRNAs, which target the 3' UTR of EZH2 and other Polycomb-associated transcripts. We show that the WT1(+KTS) isoform binds to the 5' UTR of EZH2 and interacts directly with the miRNA-containing RISC to enhance post-transcriptional inhibition. These observations suggest a novel mechanism through which WT1 regulates the transition from resting stem cell to activated progenitor cell during nephrogenesis. Our findings also offer a plausible explanation for the fact that Wilms tumors can arise either from loss of WT1 or loss of miRNA processing enzymes.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Argonaute; Enhancer of Zeste 2; Wilms tumor 1; dicer; kidney development; mesenchymal stem cells (MSCs); microRNA (miRNA); polycomb

Mesh:

Substances:

Year:  2015        PMID: 26655220      PMCID: PMC4759161          DOI: 10.1074/jbc.M115.678029

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Wilms' tumour: connecting tumorigenesis and organ development in the kidney.

Authors:  Miguel N Rivera; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  Target genes of the WNT/beta-catenin pathway in Wilms tumors.

Authors:  Birgit Zirn; Birgit Samans; Stefanie Wittmann; Thorsten Pietsch; Ivo Leuschner; Norbert Graf; Manfred Gessler
Journal:  Genes Chromosomes Cancer       Date:  2006-06       Impact factor: 5.006

3.  Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene.

Authors:  Murielle M Akpa; Diana M Iglesias; Lee Lee Chu; Marta Cybulsky; Cristina Bravi; Paul R Goodyer
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

4.  Biallelic DICER1 mutations occur in Wilms tumours.

Authors:  M K Wu; N Sabbaghian; B Xu; S Addidou-Kalucki; C Bernard; D Zou; A E Reeve; M R Eccles; C Cole; C S Choong; A Charles; T Y Tan; D M Iglesias; P R Goodyer; W D Foulkes
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996

5.  Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT.

Authors:  V Huff; H Miwa; D A Haber; K M Call; D Housman; L C Strong; G F Saunders
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

6.  RNA binding by the Wilms tumor suppressor zinc finger proteins.

Authors:  A Caricasole; A Duarte; S H Larsson; N D Hastie; M Little; G Holmes; I Todorov; A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 7.  Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription?

Authors:  J P Charlieu; S Larsson; K Miyagawa; V van Heyningen; N D Hastie
Journal:  J Cell Sci Suppl       Date:  1995

Review 8.  Multiple roles for the Wilms' tumor suppressor, WT1.

Authors:  R Davies; A Moore; A Schedl; E Bratt; K Miyahawa; M Ladomery; C Miles; A Menke; V van Heyningen; N Hastie
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

9.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing.

Authors:  S H Larsson; J P Charlieu; K Miyagawa; D Engelkamp; M Rassoulzadegan; A Ross; F Cuzin; V van Heyningen; N D Hastie
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

10.  Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.

Authors:  Giovana T Torrezan; Elisa N Ferreira; Adriana M Nakahata; Bruna D F Barros; Mayra T M Castro; Bruna R Correa; Ana C V Krepischi; Eloisa H R Olivieri; Isabela W Cunha; Uri Tabori; Paul E Grundy; Cecilia M L Costa; Beatriz de Camargo; Pedro A F Galante; Dirce M Carraro
Journal:  Nat Commun       Date:  2014-06-09       Impact factor: 14.919

View more
  3 in total

1.  Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination.

Authors:  Emily A Voigt; Iana H Haralambieva; Beth L Larrabee; Richard B Kennedy; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

Review 2.  Wilms tumor, pleuropulmonary blastoma, and DICER1: case report and literature review.

Authors:  Olivier Abbo; Kalitha Pinnagoda; Laurent Brouchet; Bertrand Leobon; Frédérique Savagner; Isabelle Oliver; Philippe Galinier; Marie-Pierre Castex; Marlène Pasquet
Journal:  World J Surg Oncol       Date:  2018-08-10       Impact factor: 2.754

3.  Transferability of miRNA-technology to bioprocessing: Influence of cultivation mode and media.

Authors:  Ann-Cathrin Leroux; Elisabeth Bartels; Luise Winter; Melanie Mann; Kerstin Otte; Christoph Zehe
Journal:  Biotechnol Prog       Date:  2020-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.